-
Mashup Score: 44Terms of Access and Disclaimer for Use - 16 day(s) ago
By accessing this site, you agree to the Terms of Access and Disclaimer for Use as outlined in the Terms of Use tab Each diamond represents the values of the risk of death (y axis) and kidney failure (x axis) at years 1 to 5. Note that people with kidney failure may die within the prediction timeframe. This app has been developed by Pietro Ravani, Jose Aponte and Emir Sevinc (software maintainer). The app is hosted at the University of Calgary, Cumming School of Medicine. KDpredict was published in the
Source: kdpredict.comCategories: General Medicine News, NephrologyTweet
-
Mashup Score: 26Mortality risk in patients on hemodiafiltration versus hemodialysis: a ‘real-world’ comparison from the DOPPS - 17 day(s) ago
AbstractBackground. With its convective component, hemodiafiltration (HDF) provides better middle molecule clearance compared with hemodialysis (HD) and is
Source: academic.oup.comCategories: General Medicine News, NephrologyTweet
-
Mashup Score: 8
Over 110 weeks, treatment with sparsentan versus maximally titrated irbesartan in patients with IgA nephropathy resulted in significant reductions in proteinuria and preservation of kidney function.
Source: www.thelancet.comCategories: General Medicine News, NephrologyTweet
-
Mashup Score: 32Targeting the Alternative Complement Pathway With Iptacopan to Treat IgA Nephropathy: Design and Rationale of the APPLAUSE-IgAN Study - 17 day(s) ago
Targeting the alternative complement pathway (AP) is an attractive therapeutic strategy because of its role in immunoglobulin A nephropathy (IgAN) pathophysiology. Iptacopan (LNP023), a proximal complement inhibitor that specifically binds to factor B and inhibits the AP, reduced proteinuria and attenuated AP activation in a Phase 2 study of patients with IgAN, thereby supporting the rationale for its evaluation in a Phase 3 study.
Source: www.kireports.orgCategories: General Medicine News, NephrologyTweet
-
Mashup Score: 41Terms of Access and Disclaimer for Use - 17 day(s) ago
By accessing this site, you agree to the Terms of Access and Disclaimer for Use as outlined in the Terms of Use tab Each diamond represents the values of the risk of death (y axis) and kidney failure (x axis) at years 1 to 5. Note that people with kidney failure may die within the prediction timeframe. This app has been developed by Pietro Ravani, Jose Aponte and Emir Sevinc (software maintainer). The app is hosted at the University of Calgary, Cumming School of Medicine. KDpredict was published in the
Source: kdpredict.comCategories: General Medicine News, NephrologyTweet
-
Mashup Score: 6
Pregnancy in females with kidney disease is not uncommon and is associated with adverse maternal and fetal outcomes. The use of contraception in females with chronic kidney disease remains low. We sought to describe the perspectives of female patients with advanced chronic kidney disease on the use of contraception.
Source: www.kidneymedicinejournal.orgCategories: General Medicine News, NephrologyTweet
-
Mashup Score: 24X-Linked Kidney Disorders in Women - PubMed - 17 day(s) ago
A number of genes that cause inherited kidney disorders reside on the X chromosome. Given that males have only a single active X chromosome, these disorders clinically manifest primarily in men and boys. However, phenotypes in female carriers of X-linked kidney conditions are becoming more and more …
Source: pubmed.ncbi.nlm.nih.govCategories: General Medicine News, NephrologyTweet
-
Mashup Score: 1Stopping Renin-Angiotensin System Inhibitors in Patients with Advanced CKD and Risk of Adverse Outcomes: A Nationwide Study - PubMed - 17 day(s) ago
In this nationwide observational study of people with advanced CKD, stopping RAS inhibition was associated with higher absolute risks of mortality and major adverse cardiovascular events, but also with a lower absolute risk of initiating KRT.
Source: pubmed.ncbi.nlm.nih.govCategories: General Medicine News, NephrologyTweet
-
Mashup Score: 3Keep Calm and Carry on Inhibiting the RAS — NephJC - 17 day(s) ago
This week, we will discuss the STOP ACEi trial, a poster from Kidney Week but published in the NEJM. Should we stop RAS inhibition at an arbitrary GFR or bravely carry on?
Source: www.nephjc.comCategories: General Medicine News, NephrologyTweet
-
Mashup Score: 4Donal Joseph O’Donoghue | The UK Kidney Association - 17 day(s) ago
Professor Donal O’Donoghue was a clinical nephrologist and the first National Clinical Director for Kidney Care for England. A passionate advocate on behalf of people with kidney disease, he became a leading force driving the development of effective nephrology services in the UK and beyond. He tragically died suddenly when still at the height of his professional career. Donal
Source: ukkidney.orgCategories: General Medicine News, NephrologyTweet
First up for the #ISNWCN LBCT is @pietro_ravani on a new prediction model Model is already available here https://t.co/vlbycPjNtT Paper just went live on @bmj_latest https://t.co/jjEPj8KbfM